CEACAM5 and gastric cancer: In order to evaluate the clinical performance of the combined use of blood biomarker (i.e., CEA level) and saliva biomarker (i.e., PPL expression level), we recruited an independent patient cohort with 60 GC patients and 60 healthy controls in the validation phase.